Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/9670
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Aslan, O. | - |
dc.contributor.author | Yaylalı, Yalın Tolga | - |
dc.contributor.author | Yildirim, S. | - |
dc.contributor.author | Yurtdas, M. | - |
dc.contributor.author | Şenol, Hande | - |
dc.contributor.author | Ugur-Yildiz, M. | - |
dc.contributor.author | Ozdemir, M. | - |
dc.date.accessioned | 2019-08-16T13:04:09Z | |
dc.date.available | 2019-08-16T13:04:09Z | |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1076-0296 | - |
dc.identifier.uri | https://hdl.handle.net/11499/9670 | - |
dc.identifier.uri | https://doi.org/10.1177/1076029614546327 | - |
dc.description.abstract | Safety issues have been raised about dabigatran. We aimed to investigate the occurrence of safety outcomes in patients who had atrial fibrillation and a risk of stroke. We analyzed 439 patients prescribed dabigatran (n = 220) or warfarin (n = 219). Ischemic stroke occurred in 15 (6.8%) patients in the warfarin group versus 5 (5.2%) patients in the 110-mg group versus 1 (0.8%) patient in the 150-mg dabigatran group (P =.015). Intracranial hemorrhage occurred in 6 (2.7%) patients in the warfarin group versus 3 (2.4%) patients in the 150-mg dabigatran group (P =.104). Death from any cause occurred in 10 (4.6%) patients in the warfarin group versus 1 (1.0%) patient in the 110-mg dabigatran group (P =.005). Dabigatran was associated with less ischemic stroke and death from any cause than warfarin. Dabigatran may be a better option for stroke prophylaxis, where recommended monitoring with warfarin is suboptimal. © SAGE Publications. | en_US |
dc.language.iso | en | en_US |
dc.publisher | SAGE Publications Inc. | en_US |
dc.relation.ispartof | Clinical and Applied Thrombosis/Hemostasis | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | drug monitoring | en_US |
dc.subject | hemorrhage | en_US |
dc.subject | myocardial infarction | en_US |
dc.subject | stroke | en_US |
dc.subject | thromboembolism | en_US |
dc.subject | dabigatran | en_US |
dc.subject | warfarin | en_US |
dc.subject | adult | en_US |
dc.subject | aged | en_US |
dc.subject | arthralgia | en_US |
dc.subject | Article | en_US |
dc.subject | atrial fibrillation | en_US |
dc.subject | brain hemorrhage | en_US |
dc.subject | brain ischemia | en_US |
dc.subject | cerebrovascular accident | en_US |
dc.subject | dizziness | en_US |
dc.subject | drug dose comparison | en_US |
dc.subject | drug safety | en_US |
dc.subject | dyspepsia | en_US |
dc.subject | dyspnea | en_US |
dc.subject | female | en_US |
dc.subject | fluid retention | en_US |
dc.subject | headache | en_US |
dc.subject | heart infarction | en_US |
dc.subject | human | en_US |
dc.subject | insomnia | en_US |
dc.subject | lung embolism | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | nausea and vomiting | en_US |
dc.subject | priority journal | en_US |
dc.subject | rash | en_US |
dc.subject | retrospective study | en_US |
dc.subject | side effect | en_US |
dc.subject | treatment outcome | en_US |
dc.subject | Turkey (republic) | en_US |
dc.subject | urinary dysfunction | en_US |
dc.subject | visual disorder | en_US |
dc.subject | weight gain | en_US |
dc.subject | weight reduction | en_US |
dc.subject | chemically induced | en_US |
dc.subject | clinical trial | en_US |
dc.subject | comparative study | en_US |
dc.subject | middle aged | en_US |
dc.subject | multicenter study | en_US |
dc.subject | Stroke | en_US |
dc.subject | Turkey | en_US |
dc.subject | very elderly | en_US |
dc.subject | Adult | en_US |
dc.subject | Aged | en_US |
dc.subject | Aged, 80 and over | en_US |
dc.subject | Atrial Fibrillation | en_US |
dc.subject | Brain Ischemia | en_US |
dc.subject | Dabigatran | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Male | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Warfarin | en_US |
dc.title | Dabigatran versus warfarin in atrial fibrillation: Multicenter experience in Turkey | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 22 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.startpage | 147 | |
dc.identifier.startpage | 147 | en_US |
dc.identifier.endpage | 152 | en_US |
dc.identifier.doi | 10.1177/1076029614546327 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.pmid | 25115764 | en_US |
dc.identifier.scopus | 2-s2.0-84957710536 | en_US |
dc.identifier.wos | WOS:000370068600005 | en_US |
dc.identifier.scopusquality | Q2 | - |
dc.owner | Pamukkale University | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.03. Basic Medical Sciences | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
SCOPUSTM
Citations
10
checked on Nov 16, 2024
WEB OF SCIENCETM
Citations
10
checked on Nov 21, 2024
Page view(s)
54
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.